908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook
MASSBOSTON--(BUSINESS WIRE)-- #VipIR--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended June 30, 2025. “We executed with urgency and discipline in the second quarter, driving strong top-line growth while advancing key structural initiatives to strengthen our financial profile,” said Kevin J. Knopp, CEO and Co-founder. “We deli
908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors
MASSBOSTON--(BUSINESS WIRE)-- #CBRN--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 15 years at the U.S. Department of Defense (DoD), Dr. Vann held several leadership positions overseeing nuclear, chemical, and biological defense programs. The company also announces that Jeff George, a veteran biopharma leader, has stepped down from its Board of Directors
908 Devices Appoints Christopher D. Brown to its Board of Directors
MASSBOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company’s Chief Technology Officer & Vice President of Research & Development from February 2
908 Devices' MX908 Deployed By Romanian Customs For Real-Time Drug And Explosive Detection At Borders
MASS908 Devices Affirms FY2025 Sales Guidance of $53.00M-$55.00M vs $55.17M Est
MASS908 Devices Q1 2025 Adj. EPS $(0.27), Inline, Sales $11.78M Miss $11.93M Estimate
MASS908 Devices Receives $2M Order From The Texas Department Of Public Safety For Drug Detection And Mitigation
MASS908 Devices Expects Q1 Revenue From Cont. Ops. To Be At Least $11.5M Vs $7.4M Last Year, Reflecting Reported Growth Of About 55%
MASS908 Devices Receives $1.7M Order From Ministry Of Health Of Ukraine For Its Handheld Mass Spec Device
MASS908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
MASSRepligen acquires 908 Devices' desktop portfolio for $70 million, enhancing its bioprocessing analytics. 908 Devices shifts focus to handheld growth, forecasting revenue gains.
908 Devices Q4 2024 Adj EPS $(0.27) Beats $(0.35) Estimate
MASSTrading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
MASS908 Devices Now Expects To Achieve Adjusted EBITDA Positivity By Q4 2025 And Cash Flow Positivity In 2026
MASS908 Devices Expects 2025 Revenues From Cont Ops Of $53M - $55M, Representing 11% - 15% YoY Growth; Expects Further Acceleration Above 20% In 2026
MASS908 Devices Q4 Sales $18.82M Beat $16.39M Estimate
MASSRepligen Purchases 908 Devices' Desktop Portfolio Of Four Devices For Bioprocessing Process Analytical Technology Applications For $70M Cash
MASSTrading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending
MASSStephens & Co. Reiterates Overweight on 908 Devices, Maintains $6 Price Target
MASS908 Devices Reports Preliminary FY24 Revenue Of $58M (Est $56.78M), Reflecting Reported Growth Of 15% YoY And Meeting High End Of Revenue Guidance
MASS908 Devices Reports Preliminary Q4 Revenue Of $17.2M (Est $16.177M), Reflecting Reported Growth Of Approximately 20% YoY
MASS908 Devices And Getinge Announce Their Collaboration To Integrate Getinge's Bioreactors With 908 Devices' MAVEN For Automated Control Of Glucose And Lactate Levels In Cell Cultures
MASS